Medical/Pharmaceuticals

Terran Biosciences announces licensing deal with Columbia University for exclusive worldwide rights to proprietary CNS biomarker software platform

NEW YORK, March 16, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics and technologies for neurological and psychiatric diseases, has entered into an agreement withColumbia University ("Columbia") and...

2022-03-16 20:38 4700

Innoforce and Hibiscus BioVentures Announce Strategic Partnership to Enable Development of Advanced Therapies

- Partnership enables Hibiscus BioTechnology Studio Companies access to Innoforce's advanced therapies drug development capabilities - HANGZHOU, China and ROCKVILLE, Md., March 16, 2022 /PRNewswire/ -- Innoforce, a global development and biomanufacturing company focused on Advanced Therapy Medic...

2022-03-16 19:00 2868

Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab

SAN DIEGO and SUZHOU, China, March 16, 2022 /PRNewswire/ -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced FDA clearance to proceed with a Phase1b/2 clinical trial of its anti-CTLA-4 monoclonal antib...

2022-03-16 19:00 4072

Mentice receives order of ten (10) VIST simulator systems in China for a value exceeding 500,000 USD

STOCKHOLM, March 16, 2022 /PRNewswire/ -- Mentice, a world leader in simulation solutions for image-guided interventional therapies, announced today that Siemens Healthineers China via an official importation agent, has placed an order of ten (10) Mentice VIST simulator packages including the Sie...

2022-03-16 15:43 2319

Beyond a platform, Ping An Good Doctor aiming to be a pillar of China's healthcare sector

HONG KONG and SHANGHAI, March 16, 2022 /PRNewswire/ -- In the second year of the COVID-19 pandemic,Ping An Good Doctor's value proposition of providing users with an "easier, faster and more affordable" digital health experience found resonance with all segments of society. There is still a long...

2022-03-16 15:17 4220

Chang Il-Moo, a former head of R&D department at KGC, wins James A. Duke award from the American Botanical Council

SEOUL, South Korea and ANAHEIM, Calif., March 16, 2022 /PRNewswire/ -- Chang Il-Moo, who successively served as the head of R&D department at the Korea Ginseng Corporation (KGC, CEOKim Jae-Su), won the 2021 Duke Award, the top writing award granted by the American Botanical Council (ABC), forA Hi...

2022-03-16 15:15 2853

SNIPR BIOME expands its Executive Management team and opens offices in the US and UK

COPENHAGEN, Denmark, March 16, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, today announced the appointment of Jasper Clube as Chief Intellectual Property Officer from 1 February 2022 and Stephanie Krebs as Chief Business Officer from 14 March 2022. ...

2022-03-16 14:28 2209

Pasture Announces First Halal-Certified Surgical N95 Masks for Healthcare and Public Use

SINGAPORE, March 16, 2022 /PRNewswire/ -- Pasture Group, the leading global medical device manufacturer and pharmaceutical company inSingapore, unveils its accreditation as the world's top halal-certified US FDA-approved N95 mask producer for healthcare and public use.

2022-03-16 13:00 3256

Gene Solutions Makes Earlier Detection of Cancer A Possibility of the Future

HO CHI MINH CITY, Vietnam, March 16, 2022 /PRNewswire/ -- The scientific research team fromGene Solutions  has invented a SPOT-MAS liquid biopsy technology to enhance early-stage detection of many cancers. This technology is to expect to reshape the landscape of early c...

2022-03-16 09:36 4880

Brii Bio Announces that National Health Commission of China Adds Amubarvimab/Romlusevimab Combination to its COVID-19 Diagnosis and Treatment Guidelines (9th Pilot Edition)

The amubarvimab/romlusevimab combination is the first locally-discovered and approved SARS-CoV-2 target-specific treatment inChina, through a randomized, double-blind and placebo-controlled trial In vitro tests shows that amubarvimab/romlusevimab combination retains neutralizing activity against...

2022-03-16 09:00 4460

Korea Health Industry Development Institute operates Korean Pavilion at 'HIMSS Global Health Conference & Exhibition'

- Presenting the latest healthcare technologies with leading innovation companies ofSouth Korea ORLANDO, Fla., March 15, 2022 /PRNewswire/ -- Korea Health Industry Development Institute (KHIDI) announced its operation of the Korean pavilion at the 2022 HIMSS Global Health Conference& Exhibition ...

2022-03-16 06:44 2558

United Imaging Receives Contract from Vizient for its X-ray and Magnetic Resonance Imaging Systems

HOUSTON, March 15, 2022 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, has received a contract from Vizient, Inc., for its entire portfolio of DR (X-Ray) and MR (magnetic resonance) systems. The contract expands the number of modalities off...

2022-03-15 21:00 2498

Evercare Group launches Evercare Foundation to help bridge the gap in inequality in healthcare

- The Foundation will provide long-term solutions to improve healthcare access inAfrica and South Asia, while contributing to the 2030 Sustainable Development Goals. ISLAMABAD, Pakistan, March 15, 2022 /PRNewswire/ -- The Evercare Group today announced the launch of the Evercare Foundation, a no...

2022-03-15 20:22 2166

ROKIT Healthcare's Latest Paper About Its AI Technology Has Been Accepted to CVPR 2022

SEOUL, South Korea, March 15, 2022 /PRNewswire/ -- ROKIT Healthcare, a global hyper-personalized organ regeneration company, announced onMarch 7th that its paper about the "AI and 3D bioprinting convergence technology for regenerative treatments" has been accepted to 2022 IEEE/CVF Conference on C...

2022-03-15 20:00 2752

I-Mab Provides Updates Regarding Holding Foreign Companies Accountable Act

SHANGHAI and GAITHERSBURG, Md., March 15, 2022 /PRNewswire/ -- I-Mab ( "I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today provides updates on the recent development relating ...

2022-03-15 20:00 2325

Business Update on ASC10, an Oral Double Prodrug against COVID-19

HANGZHOU and SHAOXING, China, March 15, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the business update on its oral double prodrug ASC10 against Coronavirus Disease 2019 (COVID-19): By taking measures below, the manufacturing cost of ASC10 reduced significantly, which ...

2022-03-15 19:55 3957

Animal health company Emollivet raises capital and strengthens team

GOTHENBURG, Sweden, March 15, 2022 /PRNewswire/ -- Emollivet, the animal health company that develops user-friendly skin care products for animals, is raising capital and recruiting key people. The new share issue, a rights issue to existing owners, amounts toSEK 5 million. On 3rd March, Emolliv...

2022-03-15 15:48 2074

Ascentage Pharma Announces First Patient Dosed in China in the Pivotal Phase II Study of Lisaftoclax (APG-2575) in R/R CLL/SLL

SUZHOU, China, and ROCKVILLE, Md., Mar. 14, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has dosed the first patient in the pivota...

2022-03-15 14:52 2325

Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress

Sirnaomics CTO Dmitry Samarsky, PhD, to Also Present OPT Congress Opening Remarks HONG KONG, March 15, 2022 /PRNewswire/ -- Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will pre...

2022-03-15 12:47 3701

Everest Medicines to Announce Full-Year 2021 Financial Results on March 29, 2022

SHANGHAI, March 15, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs inAsia Pacific markets, today announced that it will...

2022-03-15 09:00 4265
1 ... 580581582583584585586 ... 643